Role of Tocilizumab in Combating Cytokine Storm in Moderate & Severe Covid 19 Patients: Retrospective Observational Study

Nithish Sattoju *

Medisys Hospitals, LB Nagar, Hyderabad, Telangana, India.

Santosh Gattu

Medisys Hospitals, LB Nagar, Hyderabad, Telangana, India.

Sai Sashank Merugu

Medisys Hospitals, LB Nagar, Hyderabad, Telangana, India.

Vydhika Anneboina

Chilkur Balaji College of Pharmacy, Telangana, India.

Sai Ram Ganapaka

Chilkur Balaji College of Pharmacy, Telangana, India.

Anvesh Maram

Chilkur Balaji College of Pharmacy, Telangana, India.

*Author to whom correspondence should be addressed.


Abstract

Background: The wide spread of COVID-19 disease and mortality associated with it as never seen before urged the medical research field to formulate and investigate the efficacy of various new drugs alongside with the existing drugs.

Objective: To evaluate the potential benefits of Tocilizumab (TCZ) in addition to the Standard of Care (SoC) in reducing mortality in moderate & severely ill COVID 19.

Methodology: Study population is sorted by 1:1 matching depending on the High-Resolution Computed Tomography (HRCT) Chest CT Severity Score. Outcome is measured as deaths, discharge with or without Long Term Oxygen Therapy (LTOT) along with clinical improvement of the patient measured using 9 points ordinary scale score of WHO and length of stay in Intensive Care Unit (ICU) post administration & levels of inflammatory markers (CRP, IL 6) on day of administration- baseline (D0), 1- & 3-days post administration (D+1 & D+3). The group received TCZ+SoC is considered as Test Group and the group received only SoC as Control Group.

Results: Deaths and discharge with LTOT were slightly higher in test group with OR 1.68 & 1.63 respectively. Clinical improvement in terms of 9-point ordinary scale score & difference in the levels of CRP & IL 6 was insignificant in both the groups. No difference in post administration ICU stay is observed between the groups.

Conclusions: Our study concludes no marked benefits with the addition of TCZ to the SoC in treating moderate and severe COVID 19 patients.

Keywords: COVID 19, tocilizumab, standard of care, inflammatory markers, 9-point ordinary scale developed by W.H.O


How to Cite

Sattoju, N., Gattu, S., Merugu, S. S., Anneboina, V., Ganapaka, S. R. and Maram, A. (2022) “Role of Tocilizumab in Combating Cytokine Storm in Moderate & Severe Covid 19 Patients: Retrospective Observational Study”, Journal of Pharmaceutical Research International, 34(53B), pp. 50–58. doi: 10.9734/jpri/2022/v34i53B7231.

Downloads

Download data is not yet available.

References

Khanna RC, Cicinelli MV, Gilbert SS, Honavar SG, Murthy GVS. COVID-19 pandemic: Lessons learned and future directions. Indian J Ophthalmol. 2020;68 (5):703-710.

Andrews MA, Areekal B, Rajesh K, Krishnan J, Suryakala R, Krishnan B, et al. First confirmed case of COVID-19 infection in India: A case report. Indian J Med Res. 2020;151(5):490.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; 382(13):1199-1207.

Billah MA, Miah MM, Khan MN. Reproductive number of coronavirus: A systematic review and meta-analysis based on global level evidence. Plos One. 2020;15(11):e0242128.

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.

Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269-270.

Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5): 405-407.

Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943.

Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;7(6):998-1002.

Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020;15(5):700-704.

Xu X, Han M, Li T, Sun W, Wang D, Fu B et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970.

Song SNJ, Yoshizaki K. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opin Drug Metab Toxicol. 2015;11(2):307-316.

Oldfield V, Dhillon S, Plosker GL, Alten R, Yamanaka H. Tocilizumab A review of its use in the management of rheumatoid arthritis.

Alten R. Tocilizumab: A novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2011;3(3):133-149.

Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020;50(5):397-400.

Nithish Sattoju, Sai Sashank Merugu, Santosh Gattu, Sai Ram Ganapaka, Vydhika Anneboina. Role of cytosorb in severe Covid 19 patients to combat cytokine storm- a case series of 3 patients. Glob J Med Res. 2022;22(F5):13-20. [Cited 2022 Nov.13].

Available:https://medicalresearchjournal.org/index.php/GJMR/article/view/101776

Xu X, Han M, Li T, Sun W, Wang D, Fu B et al. Effective treatment of severe Covid-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970.

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814-818.

Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10): 3959-3964.

Rojas-Marte G, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: A case–controlled study. QJM: An International Journal of Medicine. 2020; 113(8):546.

Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F et al. Tocilizumab for treatment of severe COVID-19 patients: Preliminary results from smatteo Covid19 registry (SMACORE). Microorganisms. 2020; 8(5).

Campochiaro C, Della-Torre E, Cavalli G, de Luca G, Ripa M, Boffini N et al. Efficacy and safety of tocilizumab in severe Covid-19 patients: A single-centre retrospective cohort study. Eur J Intern Med. 2020; 76:43.

Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36.